Abstract: A bandage and method for securing a tension member comprising a central body and a plurality of tabs disposed about the central body. A tension member may be disposed across or through a slit or aperture of the central body. A body adhesive on the lower surface of the central body may secure the bandage to the patient. The tension member may then be pulled across the upper surface of the central body and a first tab may be folded over and adhered to the tension member and central body. The tension member may then be pulled back across the first tab and a second tab may be folded over and adhered to the tension member and first tab. Likewise, the tension member may then be pulled back across the second tab and a third tab may be folded over and adhered to the tension member and second tab.

Abstract: The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration.

Abstract: The invention provides methods and compositions for wound treatment and/or blood clot formation, e.g., arresting the flow of blood from an open wound. The methods and compositions provide for promoting and accelerating wound healing and optionally provide for inhibition of microbial infection and/or a local analgesic effect.

Abstract: Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.

Abstract: The present disclosure provides a brush polymer, including: a linear polymer main chain; and brush structural side chains, including: a hydrophobic molecular branch, and a hydrophilic molecular branch and/or an anti-biofilm/or an anti-microbial molecular branch, wherein the linear polymer main chain is conjugated to the side chains by covalent bonds formed between a hydroxyl group and a reactive functional group, wherein the reactive functional group includes: isocyanate, carboxyl, or epoxy. The present disclosure also provides a medical application of the brush polymer.

Abstract: The invention relates to an antimicrobial dressing, an anti-microbial composition and use thereof. The dressing comprises: chlorhexidine and/or a pharmaceutically acceptable salt thereof in a solid state in a quantity, calculated as an equivalent weight of chlorhexidine digluconate/surface of dressing, comprised between 0.013 and 2 g/m2; and silver and/or a pharmaceutically-acceptable salt in the solid state in a quantity, calculated as an equivalent weight of metallic silver/surface of dressing of greater than or equal to 0.1 g/m2. The composition comprises: chlorhexidine and/or a pharmaceutically acceptable salt thereof in a solid state in a relative weight/weight percentage, calculated as an equivalent weight of chlorhexidine digluconate/total weight of the composition, comprised between 0.01% and 0.09%; and silver and/or a pharmaceutically acceptable salt thereof in the solid state in a relative percentage weight/weight comprised between 0.00008% and 0.

Abstract: Methods of treating disorders mediated by ?-catenin comprising administration of Nefopam compounds are provided In particular, the treatment of disorders arising from excessive or undesired expression of ?-catenin is contemplated Said compounds include Nefopam, analogues thereof, prodaigs thereof, and salts and solvates of Nefopam The ?-catenin mediated disorders are preferably selected from the group consisting of fibroproliferative disorders (such as scars, aggressive fibramtoses, and fibroses) and cancer (such as colon cancer, melanoma, liver cancer, ovarian cancer, endometrial cancer, medullobalstoma pilomatricomas, and prostate cancer)

Abstract: Provided is a wound dressing prepared from whole blood that is clotted ex vivo to form a sheet of clotted blood that is applied onto the skin over a sight of skin injury.

Abstract: The present invention includes compositions and methods for the integration of a non-allergenic nanocellulose into a wound bed. The composition may be formed into a wide variety of implants, e.g., a suture, a sheet, a compress, a bandage, a band, a prosthesis, a fiber, a woven fiber, a bead, a strip, a clasp, a prosthesis, a catheter, a screw, a bone plate, a pin, a bandage or combinations thereof.

Abstract: The present invention relates to a fluid-permeable primary dressing in strip form, having pores, perforations or honeycomb lattices, which enable the passage of fluid, further having a content of at least one heavy metal present in elemental or ionic form.

Abstract: The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.

Abstract: The aqueous thermosetting neutralized chitosan composition, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C., comprises 0.1 to 5.0 w/w %, based on the total composition, of a reacetylated chitosan having a molecular weight of not smaller than 100 kDa and a deacetylation degree of 40 to 70%, neutralized with an hydroxylated base, and 1 to 30 w/w %, based on the total composition, of a complexing agent selected from polyoses and polyols derived from polyoses. Said composition is useful for the preparation of an injectable formulation.

Abstract: A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds.

Abstract: The invention relates to octenidine or a pharmaceutical salt thereof, in particular octenidine dihydrochloride, which is intended for mutual therapeutic administration of the octenidine in solution with a polyalcohol of formula 1: (H—C—OH)a(HO—C—OH)b(H—C—H)c, where a, b, c are whole numbers, where a+b is at least 2, preferably at least 3, c is selected from 0, 1 or a number from 2 to a+b, optionally in addition to one or more aldehyde groups provided that they form (cyclic) acetals with one of the hydroxy groups or one or more keto groups optionally as acetal with one of the hydroxy groups, optionally in addition to one or more carboxylic acid groups if the polyalcohol is a cyclic acetal or acetal, preferably with ring sizes of 5 to 7 atoms, or a polymer, polyether or polyester thereof, provided that the polyalcohol exists as a polymer, polyether or polyester with at least two units of formula 1 if a+b is 2 or 3.

Abstract: The present invention relates to the use of at least one compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and to the salts and complexes thereof as cleaning agents for a wound. The invention can be used in particular for preparing bandages intended for cleaning wounds.

Abstract: Devices in which components of medical kits are carried are identifiable by means other than by the naked eye. The means for identification is attached to or integral with the device and may comprise raised and lowered surfaces that can be read by touch; serrations disposed on an edge or surface; a fluorescent coating viewable under infrared or ultraviolet light; or a pattern that is viewable using a thermal imaging device such as night vision goggles. A package for retaining a medical item includes an identifying element of a material that is selectively viewable in response to light attributes of the material. A device for the visual identification of a package containing a medical item includes an identifying element comprising a material that is visually discernible in reduced-light environments via the use of night vision devices.

Abstract: A dressing composition for use as a skin dressing comprises an elastomeric-adhesive composition, and a zeolite comprising releasably adsorbed nitric oxide. The zeolite may comprise a transition metal cation such as Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof as an extra-framework metal cation, preferably Zn. The elastomeric adhesive composition may be a hydrocolloid-adhesive composition comprising, hydrocolloid and elastomer. The dressing composition releases nitric oxide, which may have beneficial effects, when used on wounds or moist skin, with a substantially constant release rate over a long period of time. A dressing including a layer of the dressing composition has a backing layer and may have a release liner removably attached to the skin-contacting surface of the dressing layer.

Abstract: A solid buffer including one or more ion exchange materials, wherein said solid buffer has a volumetric buffering capacity greater than about 20 mM H+/(L·pH unit) and further wherein, when said material is in an environment capable of transporting H+ ions, said solid buffer is adapted to cause the death of at least one target cell within or in contact with said environment. A selectively permeable barrier layer may be provided covering the solid buffer.

Abstract: A hemostatic tissue sealant sponge and a spray for acute wounds are disclosed. The sponge comprises hydrophobically modified polymers that anchor themselves within the membrane of cells in the vicinity of the wound. The seal is strong enough to substantially prevent the loss of blood inside the boundaries of the sponge, yet weak enough to substantially prevent damage to newly formed tissue upon recovery and subsequent removal of the sponge. In examples, the polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The spray comprises hydrophobically modified polymers that form solid gel networks with blood cells to create a physical clotting mechanism to prevent loss of blood. In an example, the spray further comprises at least one reagent that increases the mechanical integrity of the clot. In another example, the reagent prevents microbial infection of the wound.

Abstract: The application discloses a method for the preparation (by extruding, injection molding or powder coating and subsequent cross-linking by irradiation with UV or visible light) of a medical device element involving a coating composition comprising: a) as the only polymer constituent(s), at least 50% by weight of poly(ethylene oxide)(s) optionally in combination with non-thermoplastic hydrophilic polymer(s), and b) low molecular weight scaffold(s) having a plurality of photo-initiator moieties covalently linked thereto and/or covalently incorporated therein, wherein the photo-initiator moieties constitute 0.01-20% by weight of the combined amount of the poly(ethylene oxide)(s), any non-thermoplastic hydrophilic polymers and the low molecular weight scaffolds.

Abstract: The invention relates to a biodegradable fleece containing (i) at least one polymer for inducing primary haemostasis, (ii) at least one non-proteinogenic, low-molecular, water-soluble activator of secondary haemostasis, and (iii) at least one non-proteinogenic, low-molecular, water-soluble inhibitor of fibrinolysis. The invention also relates to a method for producing a biodegradable fleece, in which (i) a fluidised fiber raw material, and additives if applicable, is placed in a container, (ii) the container is made to rotate, (iii) the fluidised fiber raw material is dispensed from the container by means of centrifugal forces, whereby fibers or filaments are formed, and (iv) a biodegradable fleece is produced from the fibers or filaments. The invention also relates to the use of said biodegradable fleece as a local haemostatic agent.

Abstract: The present invention relates to wound dressings having a wound contacting layer that contains a wound healing composition and which is adapted to maintain a temperature different from ambient, for example achieve and maintain a heat-absorbing effect on the underlying tissues. The specific physico-chemical structure of the devices of the invention allows fluid containment and absorption of wound secretions while avoiding skin macerations.

Abstract: A treated surface of a device (10) for implantation or for application as a wound dressing, comprises an array of plasma-activated hydrophilic cell-adhesive areas (18) having the ability to reduce fibrous reaction, is in the form of an array of islets of activation. Each islet of activation (18) has a length which is less than 6 ?m, a width which is less than 2 ?m and the distance between islets is preferably from 4 ?m to 6 ?m. The islets of activation (18) are surrounded by non-activated, non-adhesive, hydrophobic areas.

Abstract: The present invention relates to an antimicrobial wound dressing comprising chitosan-silver nanoparticles and a preparation method thereof The antimicrobial wound dressing is prepared by coating a wound dressing with chitosan and silver and drying the coated wound dressing and has an excellent property of releasing silver nanoparticles in a sustained manner.

Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.

Abstract: This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs, or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction or levels of inflammatory mediators.

Abstract: The invention relates to octenidine or a pharmaceutical salt thereof, in particular octenidine dihydrochloride, which is intended for mutual therapeutic administration of the octenidine in solution with a polyalcohol of formula 1: (H—C—OH)a(HO—C—OH)b(H—C—H)c, where a, b, c are whole numbers, where a+b is at least 2, preferably at least 3, c is selected from 0, 1 or a number from 2 to a+b, optionally in addition to one or more aldehyde groups provided that they form (cyclic) acetals with one of the hydroxy groups or one or more keto groups optionally as acetal with one of the hydroxy groups, optionally in addition to one or more carboxylic acid groups if the polyalcohol is a cyclic acetal or acetal, preferably with ring sizes of 5 to 7 atoms, or a polymer, polyether or polyester thereof, provided that the polyalcohol exists as a polymer, polyether or polyester with at least two units of formula 1 if a+b is 2 or 3.

Abstract: An anti-“Methicillin-Resistant Staphylococcus Aureus (MRSA)” chitosan containing antibacterial High Wet Modulus (HWM) rayon fiber textile for medical usage is made of the steps as following: chitin flakes made from natural shrimp or crab shells are deacetylated to generate chitosan with a high deacetylation degree of 90% or more. Next chitosan is dissolved in acetic acid and regenerated by caustic soda to form a chitosan antibacterial nanoparticles slurry, then added to HWM viscose rayon process, and spinning to produce a chitosan containing antibacterial HWM rayon fiber. The antibacterial amino groups of chitosan and the hydroxyl groups of rayon cellulose combine together via hydrogen bonding. Therefore, the fiber becomes the anti-MRSA antibacterial HWM rayon fiber containing amino groups (—NH3+). Finally the resulting HWM rayon fiber is conducted via a yarn spinning or/and weaving process to procure a medical textile with chitosan content.

Abstract: Disclosed are compositions comprising a hydrophilic polymer, a hydrophobic polymer, a silver ion, and a chlorite anion, wherein the silver ion associates with at least one hydrophilic or hydrophobic polymer, and wherein the chlorite ion associates with the hydrophilic polymer. Also disclosed are methods of making a photo-stable silver ion and chlorite ion containing wound dressing and methods of reducing or preventing infection of a wound by using the compositions and wound dressings of the present invention.

Abstract: The invention relates to a wound dressing having a backing and an antimicrobial wound contact layer, wherein the wound contact layer has a hydrophobized active ingredient.

Abstract: A wound dressing includes a backing material, and thrombin, applied to the backing material. Preferably, the backing material includes biodegradable polyester, such as electrospun polycaprolactone. The thrombin preferably includes salmon thrombin adsorbed onto the backing material. A process of fabricating a wound dressing includes applying thrombin to the backing material. Preferably, the thrombin is prepared from the plasma of a salmonid. The thrombin is applied to the backing material by adsorbing the thrombin onto the backing material, preferably after applying a detergent solution to the backing material. The dressing can be lyophilized and vacuum-sealed within an air-tight wrapping.

Abstract: The invention relates to a sterile wound dressing having a backing and a nonabsorbent elastomer wound contact layer, wherein the elastomer matrix is formed by a synthetic three-block elastomer, preferably a copolymer of polystyrene block and polyolefin block (SEPS, SEBS, SEEPS, etc.) or mixtures thereof, wherein the total polymer content is less than 3.2 wt %, in particular 3.0 wt % or less, preferably 2.6 wt % or less, and is plasticized by an apolar oil and/or petroleum jelly.

Abstract: The object of the present invention is to provide a means for utilizing cells that have effects on wound healing as wound-healing promoting materials by efficiently concentrating such cells within a short period of time. The present invention provides a wound-healing promoting material which comprises a sheet-like porous body having on its surface at least leukocytes and/or platelets, a method for producing the same, a device for producing the same, and a method for treating wound sites using the same.

Abstract: The present application discloses a method of making a surface antimicrobial by coating or forming a surface with a silver (I) periodate as well as articles of manufacture comprising a silver (I) periodate. The present application also discloses a method of preventing or reducing microbial contamination on a substrate by coating the substrate with at least one silver (I) periodate. The substrate can be a wound dressing, a medical instrument, a medical device, a metallic article, a plant or a seed.

Abstract: A dressing for application to a wound or burn is provided. The dressing includes a substrate and an amount of therapeutic healing compound applied to the substrate. The therapeutic healing compound includes a sugarcane plant extract, a gelling agent including at least one of xanthan gum and hydroxyethyl cellulose, and collagen.

Abstract: Described are hemostasis devices useful for implantation in biopsy tracts, which device comprise highly compact, dried hemostatic sponge elements. Preferred devices also include compacted sponge matrices exhibiting high density and rigidity in combination with high volumetric expandability when wetted. Also described are methods for making and using such devices.

Abstract: Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein.

Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.

Abstract: The present invention relates to a new isolated polypeptide nominated microcin S, isolated nucleic acid molecules encoding the microcin S polypeptide and primers and probes hybridizing to the nucleic acid molecules. The invention also relates to plasmids and cells comprising the nucleic acid molecules, an antibody binding to the polypeptide, compositions as well as methods for producing and using the polypeptides. The present invention further relates to medical uses for treating or preventing microbial infections, functional gastrointestinal disorders or treating a tumor. The invention further relates to a method for preserving food and a method for coating dressing material.

Abstract: This invention relates to compositions and applications for an interpolymer network delivery system containing iodine.

Abstract: A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a wound fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).

Abstract: Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil (Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a wound dressing or bandage, or formulated into a topical preparation such as an ointment, lotion or cream.

Abstract: Methods, system and compositions for making and using a bioresorbable linked dressing made of bioresorbable microspheres in various configurations are provided for use in applying reduced pressure to a wound site. The methods include manufacture of a bioresorbable dressing comprising a casing and bioresorbable microspheres in the form of a rope shape. Further, the casing of the dressing comprises pores formed by a porogen system that may be activated by external to the wound or formed in situ within the wound site. The shape of the dressing allows the dressing to be placed into the wound site such that it fills the shape and size of the wound. Embodiments include formation of various rope dressing and their use in conjunction with reduced pressure therapy.

Abstract: A composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding includes a suitable amount of a polymer or polymer-forming component, hydrogen peroxide or chemical(s) capable of forming hydrogen peroxide, or a combination of both, and a decomposing agent for hydrogen peroxide. The decomposing agent includes an endogenously or exogenously supplied catalyst (other than catalase), or both, and/or the polymer or polymer-forming component.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed.

Abstract: The present invention relates to degradation-stabilised, biocompatible collagen matrices which are distinguished in particular by the fact that they contain soluble collagen and peptide constituents, to processes for the preparation of such collagen matrices, which processes include in particular chemical crosslinking with an epoxy-functional crosslinking agent, and to the use of the collagen matrices according to the invention as a cosmetic or pharmaceutical agent, in particular for topical use, and as a wound treatment agent, as an implant or as a haemostatic agent in humans or animals, and as a scaffold for cell population in the biotechnology, basic research and tissue engineering field.

Abstract: Copper ion treatments for dermatological areas of the body include solutions, creams, lotions, gels, foams, wound dressings, skin patches and suture material, each containing copper ions that bring about therapeutic effects when the copper ion treatments are applied to dermatological tissue. Methods of treating dermatological areas of the body include treatments for use on the skin and nails to treat conditions including disease, infection, inflammation, damaged or injured tissue, tissue needing to be sutured, rashes and other undesirable dermatological conditions.

Abstract: Provided herein are biologically active solution compositions comprising one or more sacrificial proteolytic enzyme substrates, one or more preservatives, and one or more antimicrobial agents and methods of using the solution compositions to treat tissue sites, in particular chronic wounds. The compositions may be used in conjunction with negative pressure wound therapy to treat tissue sites.

Abstract: An antibacterial wound dressing is based on, or derived from, gel-forming fibres such as carboxymethyl cellulose or alginate fibres having silver ions linked thereto at some but not all of the exchangeable sites such that the distribution of silver ions over the exchangeable sites is substantially uniform. The silvered fibres for the wound dressing can be prepared by contacting an assembly of precursor gel-forming fibres having exchangeable sites under conditions which do not cause irreversible gelling of the fibres with an amount of a solution containing silver ions so as to link silver ions at some but not all of the exchangeable sites, the whole of the assembly of precursor gel-forming fibres being contacted essentially simultaneously with the entire solution containing silver ions.